Chronic disease: When in doubt, consider accrual into a randomized controlled trial (RCT)

British Journal of Clinical Pharmacology

Volumn 66, Issue 2, 2008, Pages 169-172

  Ritter, J M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOSALICYLIC ACID; ANTIRETROVIRUS AGENT; ARSPHENAMINE; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HEMOGLOBIN A1C; INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PROTEINASE INHIBITOR; RITUXIMAB; RNA DIRECTED DNA POLYMERASE INHIBITOR; STREPTOMYCIN; SULFONYLUREA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CARDIOVASCULAR RISK; CHRONIC DISEASE; CLINICAL STUDY; DISEASE MARKER; DRUG INFORMATION; EDITORIAL; ERYTHROCYTE SEDIMENTATION RATE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HISTORY OF MEDICINE; HUMAN; HYPERGLYCEMIA; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZATION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYPHILIS; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; HUMANS; PROFESSIONAL COMPETENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 47249161993     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03255.x     Document Type: Editorial

References (14)

1. The cardiac arrhythmia suppression trial (CAST) investigators. Preliminary report: Effects of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989 321 : 386 2.
2. Waldo AL, Camm AJ, de Ruyder H et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote mycardial infarction. Lancet 1996 348 : 7 12.
3. Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic congestive heart failure. N Engl J Med 1991 325 : 1468 75.
4. The xamoterol in severe heart failure study group. Xamoterol in severe heart failure. Lancet 1990 336 : 1 6.
5. Murray CJL, Laner JA, Hutubessy RCW et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular disease risk. Lancet 2003 361 : 717 25.
6. LeFanu J. The Rise and Fall of Modern Medicine. London : Abacus, Little, Brown, 1999.
7. Porter R. The Greatest Benefit to Mankind: a Medical History of Humanity from Antiquity to the Present. London : Fontana Press, Harper Collins 1997.
8. Sekar VJ, Lefebvre E, De Pauw M, Vangeneugden T, Hoetelmans RM. Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers. Br J Clin Pharmacol 2008 66 : 215 21.
9. Roustit M, Jlaiel M, Leclercq P, Stanke-Labesque F. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol 2008 66 : 179 95.
10. Maini RN, Feldmann M. The pitfalls in the development of biologic therapy. Nature Clinical Trials Practice Rheumatology 2007 3 : 1 1
11. Sizova L. Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. Br J Clin Pharmacol 2008 66 : 173 8.
12. Sailler L, Attane C, Michenot F, Canonge JM, Rostaing L, Arlet-Suau E, Arlet P, Launay F, Montastruc JL, Lapeyre-Mestre M. Rituximab off-label use for immune diseases: assessing adverse events in a single-centre drug-utilisation survey. Br J Clin Pharmacol 2008 66 : 320 2.
13. The action to control cardiovascular risk in diabetes study group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 358 : 2545 59.
14. The ADVANCE collaborative group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 358 : 2560 72.